Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of a simple, once-daily antiretroviral (ARV) regimen
consisting of a fixed-dose combination tablet containing Truvada combined with atazanavir
boosted with ritonavir in treatment naive patients.
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Atazanavir Sulfate Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Ritonavir